Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Material Litigation
confidence 95%
filed 2026-10-23
Item 8.01
BDR Pharmaceuticals has filed suit against the FDA in the U.S. District Court for the District of Columbia challenging FDA's grant of 10 years of NCE exclusivity for Phathom's VOQUEZNA product. This is material litigation that directly threatens Phathom's regulatory exclusivity and competitive position; an adverse outcome would permit generic competition earlier than anticipated and materially harm the company's business and financial prospects, as explicitly acknowledged in the forward-looking statements risk factors.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-10-23
The 6-K discloses a settlement agreement entered into on October 16, 2026, to resolve a consolidated class action lawsuit (Holland v. 9F Inc., No. 2:21-cv-00948) in which 9F was named as a defendant. The settlement provides full release of all claims and is subject to court approval. This is a material litigation settlement that would affect a reasonable investor's assessment of the company's legal and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-10-23
KT Corporation disclosed a counterclaim filed against it in an international arbitration proceeding before the PCA by the Government of Rwanda and related entities, seeking approximately USD 386 million (KRW 512.4 billion, or 2.63% of equity) in damages for alleged breach of a shareholders' agreement. This is material litigation that would affect a reasonable investor's assessment of the company's financial obligations and contingent liabilities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-22
Item 8.01
The filing discloses two stockholder complaints (Stevens v. Varex and Clark v. Varex) filed in New York Supreme Court on October 6-7, 2026, challenging the Merger Agreement and alleging disclosure deficiencies in the Definitive Proxy Statement, plus 13 demand letters with similar allegations. The complaints seek to enjoin the Merger, rescission, damages, and attorneys' fees. This is material litigation directly related to a pending material transaction (the Teledyne acquisition) that would affect investor assessment of deal risk and timing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-20
Item 8.01
The Fifth Circuit vacated the class certification order in a securities class action against Filana and its officers, a material development in ongoing litigation. The court accepted the Company's position on market efficiency and meme-stock dynamics, significantly narrowing the scope of the class and reducing litigation risk. This favorable appellate ruling on class certification is a material event affecting the registrant's legal exposure and financial contingencies.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-10-19
The 6-K discloses an adverse judgment against the Company's subsidiary Tongri Mechanical in a civil lawsuit brought by ICBC for approximately RMB9.75 million (principal and interest), with the Company's subsidiary bearing joint and severable liability as a guarantor. The Company has filed an appeal, which is pending. This is a material litigation event involving a significant financial obligation and represents a material adverse development that would affect a reasonable investor's assessment of the registrant's financial condition and contingent liabilities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-10-19
Item 8.01
The filing discloses a shareholder complaint (Garfield v. Eglin, Index No. 655801/2026, filed Oct. 9, 2026) seeking to enjoin the Merger and void shareholder approval, plus fourteen demand letters alleging disclosure deficiencies in the proxy statement. While the Company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of active litigation challenging a material transaction (the Merger) and seeking injunctive relief is a material legal event that would affect a reasonable investor's assessment of transaction risk and timing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-19
Item 8.01
This disclosure reports settlement of patent litigation with Navinta LLC regarding DOJOLVI® (triheptanoin), a marketed pharmaceutical product. The settlement grants a generic competitor a non-exclusive, royalty-free license to market a generic version beginning January 1, 2033 (potentially July 1, 2033 with pediatric exclusivity). This is material because it resolves patent protection for a marketed drug and establishes a specific date when generic competition will be permitted, directly affecting the product's commercial exclusivity and revenue potential.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-19
Item 7.01
Rekor filed a verified complaint in Delaware Court of Chancery against former director Viraj Mehta alleging breach of fiduciary duty in connection with a December 2025 financing. The complaint seeks compensatory damages, disgorgement, and restitution of director compensation. This is material litigation involving alleged misconduct by a director that directly affected a major financing transaction and the company's capital structure, warranting disclosure under Item 7.01 (Other Events) as a material legal matter.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-10-19
The filing discloses two putative securities class actions filed against Curanex and its IPO underwriters alleging material misstatements and omissions in the August 2025 IPO offering documents concerning stock-price manipulation risks and underwriter due diligence deficiencies. Both actions seek unspecified compensatory damages, rescission, and other relief. This is a material litigation disclosure under Item 8.01 that would significantly affect a reasonable investor's assessment of the company's legal and financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-10-19
Item 1.01
ZoomInfo disclosed execution of a memorandum of understanding on October 16, 2026, settling a putative securities class action lawsuit for $44 million. Although filed under Item 1.01 (Material Definitive Agreement), the substance is a material litigation settlement—the core event is resolution of a securities class action alleging false statements about the Company's business and COVID-19 pandemic effects. The $44 million settlement amount and the Company's acknowledgment that resolving the litigation is in the best interests of stockholders establish materiality to a reasonable investor.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-28
The filing discloses a jury verdict in a material insurance coverage litigation case. On September 25, 2026, a federal jury awarded Ramaco LLC $30.0 million in damages ($2.5 million for aggravation and inconvenience, $27.5 million for net economic loss) against Federal Insurance Company and ACE American Insurance Company in connection with a wrongful denial of an insurance claim arising from a 2018 silo collapse. This is a significant litigation outcome with substantial financial consequences that would materially affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-28
A securities class action lawsuit was filed on September 3, 2026 in the U.S. District Court for the Northern District of California against Unicycive Therapeutics and certain officers, alleging violations of federal securities laws related to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. This is a material securities litigation disclosure that would affect a reasonable investor's assessment of the registrant's legal and financial exposure.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-28
Item 7.01
Burford Capital disclosed a jury verdict in a patent litigation matter (Taction Technology v. Apple) awarding $5.7 billion in damages, with Burford's entitlement valued at $1.4 billion. The filing explicitly states this represents "one of the largest patent verdicts in U.S. history" and is material to investors' assessment of the company's financial position and litigation portfolio performance. While the verdict is subject to post-trial motions and appellate review, the disclosure of this significant litigation outcome is the core material event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-25
Nektar Therapeutics disclosed a jury verdict in its litigation against Eli Lilly, finding breach of the implied covenant of good faith and fair dealing in a license agreement governing rezpegaldesleukin development. The jury awarded the Company $90 million in damages plus interest. This is a material litigation settlement/judgment outcome disclosed under Item 8.01 (Other Events) that would significantly affect a reasonable investor's assessment of the company's financial position and legal standing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-25
Item 8.01
This Item 8.01 discloses preliminary court approval of a settlement of stockholder derivative litigation against Acadia Healthcare's individual defendants (directors and officers). The settlement involves a $12 million monetary payment plus $4.75 million in attorneys' fees and corporate governance reforms. The disclosure of a material litigation settlement affecting the company's governance and requiring substantial cash outlay is a core material event under the taxonomy.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-09-24
EX-99.1
This press release discloses material litigation initiated by Primech and its subsidiary Primech AI against former CTO Zhang Youwei in Singapore's High Court on August 7, 2026, involving claims of breach of contract, misrepresentation, and conspiracy related to the HYTRON autonomous robot development. The counterclaim filed September 15, 2026 alleges wrongful termination, unpaid bonuses (~US$896,000), and breach of implied duties. The litigation involves significant financial claims, intellectual property disputes, and allegations against the Company's Chairman and CEO, making it material to investor assessment of the Company's business, financial condition, and operational risks.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-23
Item 1.01
REGENXBIO settled material patent infringement litigation with Sarepta Therapeutics and Catalent regarding U.S. Patents 10,526,617 and 11,680,274 related to SRP-9001 (ELEVIDYS). The settlement involves a $39.0 million payment to the Company and termination with prejudice of all ongoing patent litigation, along with mutual covenants not to sue. This is a material litigation settlement that would affect a reasonable investor's assessment of the Company's patent portfolio and financial position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-23
Item 1.01
The filing discloses settlement of material patent infringement litigations involving Sarepta's gene therapy product ELEVIDYS and UPenn Patents. The Company had already recorded a $39.0 million litigation contingency charge in Q2 2026, and the settlement agreement resolves pending patent infringement claims and inter partes review proceedings with a $39.0 million payment to REGENXBIO, plus a covenant not to sue regarding AAVrh74-based capsid products. This is a material litigation settlement that would affect investor assessment of the registrant's patent position and product commercialization risk.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-09-23
The filing discloses Beneficient's comprehensive strategy to eliminate fraudulent indebtedness asserted by HCLP Nominees (approximately $130 million in principal and accrued interest) and equity interests held by former CEO Brad Heppner following his May 2026 federal fraud conviction. The company is actively pursuing a consensual resolution before Heppner's October 2026 sentencing, or alternatively will pursue litigation against Heppner and related parties. This represents a material legal and financial matter arising from criminal fraud that directly impacts the company's balance sheet, capital structure, and governance.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-22
Item 8.01
Beyond Meat disclosed a final judgment of $15.4 million in disgorgement of profits plus $37,500 in actual damages (totaling $15,437,500) in a trademark infringement lawsuit brought by Sonate Corporation. The court's September 18, 2026 ruling on post-trial motions resulted in a material adverse judgment against the Company, making this a significant litigation settlement/judgment that materially affects the registrant's financial position and would affect a reasonable investor's assessment.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 75%
filed 2026-09-22
Item 8.01
The Company disclosed a material dispute or litigation with IBS involving potential remedies and effects on the Company, Genefic, their assets, and Mr. Bonar. The dispute relates to the financing agreements and could materially affect the registrant's financial condition and operations.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-09-21
The 6-K discloses a court ruling in Jasper Lake Ventures One LLC v. Bioceres Crop Solutions Corp. awarding damages to plaintiffs, plus $1.4 million in costs and attorneys' fees against the Company and Guarantor Defendants. This is a material litigation outcome with quantified financial consequences that would affect a reasonable investor's assessment of the registrant's legal and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 45%
filed 2026-09-21
EX-99.1
This exhibit discloses the results of independent forensic investigations into related-party transactions, loan transactions, and hospitality expenses following trading suspension. While framed as investigation findings rather than litigation, the disclosure addresses serious governance and accounting concerns (potential connected-party violations, accounting treatment issues, compliance risks) that would materially affect investor assessment. However, the classification is uncertain because the exhibit is primarily an investigation report and remedial-action disclosure rather than a discrete legal event, and no specific litigation or regulatory enforcement action is announced.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-09-18
EX-99.1
The exhibit discloses two material legal proceedings: (1) a shareholder petition in the Grand Court of the Cayman Islands seeking purchase of shares at fair value or winding up of the Company, and (2) a putative securities class action in the U.S. District Court for the Southern District of New York on behalf of purchasers of the Company's securities between March 6, 2024 and September 11, 2024. While the Company states it does not presently believe the Cayman Islands proceedings are material, the dual disclosure of both a winding-up petition and a securities class action—combined with the voluntary advance disclosure ahead of an extraordinary general meeting—indicates material litigation that would affect a reasonable investor's assessment of legal and existential risk.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-09-14
EX-99.1
The exhibit discloses a class action lawsuit filed against Banco de Galicia y Buenos Aires S.A. (the Bank, a main subsidiary of GGAL) by a consumer association challenging the validity period of a rewards points program. Although the Bank estimates an unfavorable outcome would not have significant impact on shareholders' equity, the disclosure of material litigation—a lawsuit with potential financial and reputational consequences—is required and material to investors assessing the registrant's legal and operational risks.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-14
Item 8.01
TransparentBusiness filed suit in U.S. District Court against Universal Navigation Inc. (Uniswap Labs) seeking declaratory judgment under the Lanham Act to protect its "Unicoin" trademark. This is a material litigation disclosure under Item 8.01 involving intellectual property protection and a named defendant, with the company stating its intent to pursue the suit vigorously.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-09-11
The 6-K discloses a ruling by the Federal Court of Appeals of Tucumán in a consumer litigation matter ("Asociación de Consumidores del NOA versus Telecom Personal S.A."). The court partially reversed the trial court's judgment, confirming rejection of compensatory liability for a 2015 service outage but reversing the rejection of proportional reimbursement to users. This is a material litigation outcome that creates a direct financial obligation (reimbursement to users) and would affect investor assessment of the company's contingent liabilities.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-11
Item 8.01
This disclosure reports preliminary court approval of a settlement in a stockholder derivative action (Kanner et al. v. Biggar et al.) against Acadia's officers and directors, with a $1.5 million attorneys' fee award and mandatory adoption of corporate governance reforms for four years. The settlement resolves allegations of breach of fiduciary duty, unjust enrichment, and insider trading related to false statements about the pimavanserin sNDA deficiency and complete response letters that caused a 45%+ stock price decline. This is a material litigation settlement with significant governance consequences.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-10
Item 8.01
The filing discloses three shareholder complaints and thirteen demand letters filed in connection with the pending Zymeworks merger, alleging disclosure deficiencies in the proxy statement and seeking to enjoin or rescind the transaction. While the company denies merit and voluntarily supplements disclosures to minimize litigation burden, the existence of multiple coordinated legal challenges to a material M&A transaction constitutes material litigation that would affect a reasonable investor's assessment of deal risk and timing.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-10
Item 8.01
EIDP, Inc. and Corteva reached a settlement with the State of North Carolina and multiple counties/municipalities regarding PFAS claims and Fayetteville Works site-related claims. The Company's direct payment obligation is approximately $66 million over 15 years, plus a guarantee of Chemours' share (29% of total) and establishment of a $135 million reserve fund. This is a material settlement of environmental litigation that creates direct financial obligations and contingent liabilities affecting the registrant's financial position.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 90%
filed 2026-09-10
Item 1.01
Chemours settled material PFAS-related litigation brought by the State of North Carolina and 11 local entities relating to contamination at its Fayetteville Works facility and AFFF use. The settlement totals $455 million over 15 years, with Chemours' 50% share of approximately $180 million on a net present value basis, already covered by existing accruals.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-10
Item 1.01
DuPont entered into a settlement agreement with the State of North Carolina and 11 local entities to resolve PFAS-related litigation and claims, with DuPont's pre-tax share valued at approximately $126 million (net present value ~$125 million) in aggregate cash payments over 15 years. The settlement resolves multiple claims relating to PFAS contamination from the Fayetteville Works facility and AFFF use.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-10
Item 8.01
The disclosure describes a material litigation settlement arising from a January 2025 cybersecurity incident. Multiple lawsuits by individuals claiming personal information exposure were consolidated into a single action in U.S. District Court, District of New Jersey. The Company reached an agreement in principle to settle in August 2026, disclosed via joint status report on September 10, 2026. Although the Company states it does not expect material financial impact due to cyber insurance, the settlement of consolidated class-action litigation stemming from a data breach is a material legal event that would affect a reasonable investor's assessment of the registrant's litigation exposure and cybersecurity posture.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-10
Item 8.01
Qnity Electronics disclosed a $43 million indemnification liability (44% of DuPont's after-tax settlement) arising from a Settlement Agreement resolving PFAS contamination claims at the Fayetteville Works facility. This represents a material litigation settlement with quantified financial impact that would affect a reasonable investor's assessment of the company's contingent liabilities and cash obligations.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-09-09
EX-99.1
The filing discloses a class action lawsuit filed against Banco de Galicia y Buenos Aires S.A. (the Bank, a main subsidiary of GGAL) in the National Commercial Court of Buenos Aires. The lawsuit, titled "ASOCIACION CIVIL POR LOS CONSUMIDORES Y MEDIO AMBIENTE (ACYMA) v. HSBC BANK ARGENTINA S.A." alleges improper charging of card replacement fees. Although the Bank states it estimates an unfavorable resolution would not have a significant impact on shareholders' equity, the disclosure of a material class action lawsuit to the securities regulator (CNV) constitutes a material litigation event requiring disclosure under 6-K rules.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-08
Item 8.01
BJ's Wholesale Club disclosed settlement of litigation related to credit card interchange fees in which the Company was a plaintiff, resulting in a one-time pre-tax benefit of approximately $240 million. This is a material litigation settlement that will significantly impact Q3 fiscal 2026 results and is disclosed under Item 8.01 (Other Events), consistent with the material_litigation classification for material settlements.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 72%
filed 2026-09-08
Item 8.01
The filing discloses a Revised 2026 Annual Budget with aggregate budgeted expenses of $19,500,000, with the revision "primarily due to unanticipated legal costs related to litigation." While the specific litigation details are not elaborated, the material increase in budgeted expenses attributable to litigation costs constitutes a disclosure of a material legal event that would affect a reasonable investor's assessment of the Trust's financial obligations and operational costs. The litigation itself is the driver of the budget revision and thus the salient event.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-04
Item 8.01
AMC Global Media settled a material breach-of-contract litigation with Robert Kirkman, Glen Mazzara, Gale Anne Hurd, and other producers for $120 million total ($85 million cash by September 18, 2026, plus $35 million by January 31, 2027), with dismissal with prejudice and mutual releases. The company took an $85 million charge in Q3 2026 related to this settlement.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-09-02
Item 7.01
The filing discloses that EGH was added as a defendant on March 5, 2026 in a declaratory judgment claim brought by NEC Fund entities against Hecate Holdings, Hecate Energy Group, Repsol Renewables, and EGH in Delaware Court of Chancery. On August 27, 2026, the parties entered into a mutual release and settlement agreement to resolve the claims and intend to file a motion to dismiss. This settlement of material litigation involving the registrant and its parent company is a significant event affecting the business combination timeline and lender relationships, making it material to investors evaluating the transaction.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-31
Item 8.01
The disclosure reports a favorable Federal Circuit Court of Appeals decision in Exelixis, Inc. v. MSN Laboratories Private Limited affirming that three Exelixis patents (11,091,439, 11,091,440, and 11,098,015) are not invalid, which establishes a January 15, 2030 earliest effective date for FDA approval of MSN's generic ANDA. This patent litigation outcome materially affects the timing and competitive landscape for a generic competitor's market entry and is therefore a material litigation event. The filing also references ongoing separate litigation involving U.S. Patent No. 12,128,039 with trial scheduled for November 2026, further underscoring the litigation context.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-31
Item 8.01
A putative securities class action complaint (Labed v. Innventure, Inc., Case No. 1:26-cv-07377) was filed August 28, 2026 in the U.S. District Court for the Southern District of New York against the Company and certain executive officers, alleging materially false and misleading statements under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, and seeking unspecified compensatory damages.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-28
Item 8.01
This Item 8.01 discloses settlement of a putative stockholder derivative and class action lawsuit alleging breaches of fiduciary duty by JBS (majority stockholder) and company directors regarding a Charter Amendment and Tax Sharing Agreement. The settlement requires a $31 million cash payment from JBS Defendants to the Company, subject to Delaware Court of Chancery approval. This is a material litigation settlement that would affect a reasonable investor's assessment of the company's legal exposure and financial position.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-08-28
The 6-K discloses a material litigation event: a statement of claim filed on August 24, 2026, in the Central District Court of Israel against Silynxcom Ltd., its U.S. subsidiary, and two named executives (CEO Nir Klein and VP Gal Nir Klein). The Plaintiffs allege wrongful control, invalid proxies, and dilution of equity interests, seeking NIS 16.9 million in damages or transfer of 650,694 shares per plaintiff. This is a material legal proceeding involving the Company's leadership and substantial claimed damages that would affect a reasonable investor's assessment of governance and financial risk.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-26
Item 7.01
KKR disclosed settlement of a civil antitrust complaint filed by the Department of Justice's Antitrust Division regarding HSR premerger notification violations in 2021–2022 transactions. The settlement involves a $250 million payment by a KKR subsidiary and full release from all related claims and investigations.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-26
Item 8.01
The Trust filed a complaint in Massachusetts Superior Court against Anton Melchionda and Onyx Partners Ltd., LLC alleging fraud, unfair and deceptive conduct, and interference with business relationships related to a failed ~$947 million real estate transaction. The complaint alleges defendants misrepresented their funding capacity, induced the Trust into a purchase agreement, then engaged in a campaign to cloud title and block alternative sales, causing over $150 million in damages. This is material litigation involving a substantial financial claim directly affecting the Trust's core asset liquidation mission.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 85%
filed 2026-08-25
Item 8.01
The disclosure centers on a material contractual dispute over a $1.0 million earnest-money deposit for a $20.0 million real estate acquisition. The Seller asserted default on August 18, 2026, claiming entitlement to retain the Deposit, and the Company disputes this and is "pursuing their available contractual, legal and equitable rights and remedies, which may include litigation." The dispute threatens to delay or prevent the acquisition, could require impairment of the Deposit, and may result in legal expenses and adverse effects on liquidity and financial condition—all material consequences to a reasonable investor.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-08-24
Item 8.01
A jury found Cytek infringed one patent claim under the doctrine of equivalents in a patent infringement action brought by Beckman Coulter and awarded $56.11 million in damages ($20 million in lost profits and $36.11 million in royalties), although Cytek prevailed on three of four claims. The material damages award and ongoing litigation risk from post-trial motions and potential appeal materially affect the company's financial condition and legal exposure.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-08-24
The 6-K discloses three putative securities class actions filed against Linkers Industries in New York state court alleging violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 related to alleged market manipulation in IPO offerings. The Company has been served in at least one action (Morales Action) and intends to defend vigorously. This is material litigation that would affect a reasonable investor's assessment of legal and financial risk.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-08-24
Item 8.01
Zillow announced a resolution with the Federal Trade Commission and five state attorneys general regarding its multifamily rental listings syndication agreement with Redfin. The settlement, documented as a stipulated final order for equitable relief filed in federal court, allows the partnership to continue through 2030 while adding new standalone product offerings in 2027, removing legal uncertainty and affecting Zillow's rental marketplace strategy.
View raw filing on EDGAR →